Literature DB >> 7909442

Treatment of the porphyrias.

R Kauppinen1, K Timonen, P Mustajoki.   

Abstract

There are seven porphyrias which are caused by defective functions of the enzymes in the haem biosynthesis. Pathogenic mechanisms and symptoms differ greatly in individual porphyrias and, consequently, most of them require a specific therapy. Clinically, the three most important entities are acute porphyric attack, porphyria cutanea tarda and protoporphyria. For an acute porphyric attack the treatment of choice is administration of haem; the other measures are elimination of precipitating factors and symptomatic therapy for many associated symptoms. Porphyria cutanea tarda is controlled by removal of iron by phlebotomies or with low-dose chloroquine. Skin symptoms in protoporphyria can be alleviated with betacaroten but there is no effective procedure to normalize disturbed porphyrin metabolism; hepatic failure seen in some patients may need a liver transplantation. The only effective treatment in congenital erythropoietic porphyria is probably a bone marrow transplantation. No satisfactory treatment is available for very rare delta-aminolevulinic acid dehydrase deficiency porphyria.

Entities:  

Mesh:

Year:  1994        PMID: 7909442     DOI: 10.3109/07853899409147324

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  6 in total

1.  Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.

Authors:  Eliane Sardh; Lillan Rejkjaer; Dan E H Andersson; Pauline Harper
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Porphyria and vampirism: another myth in the making.

Authors:  A M Cox
Journal:  Postgrad Med J       Date:  1995-11       Impact factor: 2.401

Review 3.  [Hepatic porphyrias and alcohol].

Authors:  M O Doss; A Kühnel; U Gross; I Sieg
Journal:  Med Klin (Munich)       Date:  1999-06-15

Review 4.  Erythropoietic and hepatic porphyrias.

Authors:  U Gross; G F Hoffmann; M O Doss
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

5.  AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.

Authors:  Makiko Yasuda; David F Bishop; Mary Fowkes; Seng H Cheng; Lin Gan; Robert J Desnick
Journal:  Mol Ther       Date:  2009-10-27       Impact factor: 11.454

6.  Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.

Authors:  Annika Johansson; Christer Möller; Jens Fogh; Pauline Harper
Journal:  Mol Med       Date:  2003 Sep-Dec       Impact factor: 6.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.